Cellectar Biosciences Inc. (NASDAQ: CLRB) reported efficacy data from its Phase 2b CLOVER WaM clinical trial of iopofosine I 131 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE